SpeeDx announce a collaborative agreement with GSK to supply tests and technology

SpeeDx tests and technology will be used to support GSK antibiotic clinical trials
News Source: SpeeDx Pty. Ltd.
2019-06-25 10:14
SYDNEY--(Business Wire/Korea Newswire) June 25, 2019 -- SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed a collaborative agreement with GSK, to provide a combination of existing tests and custom test development to support certain GSK antibiotic clinical trials and new product development.

“We welcome this extension of the utility and application of our tests and technology,” said Colin Denver, SpeeDx CEO. “SpeeDx has a demonstrated commitment to improve patient care, and our tests currently used in clinical practice are supporting Resistance Guided Therapy, positively impacting cure rates and helping to minimise the spread of antimicrobial resistant infections.”

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information about SpeeDx please see: https://plexpcr.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190624005302/en/
Media Contact: SpeeDx   Australia, New Zealand and Europe   Madeline O’Donoghue   +61 406 582 808     RCI Healthcare Public Relations   United States   Rick Roose   +1 415 202 4445
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.   배포 안내 >
같은 분야 보도자료 보기
  • 이 보도자료를 공유하세요
  • SpeeDx announce a collaborative agreement with GSK to supply tests and technology
주제별 보도자료
지역별 보도자료
더 알아보기